Pharmacological enhancement of ex vivo gene therapy neuroprotection in a rodent model of retinal degeneration

Ophthalmic Research

Volumn 47, Issue 1, 2011, Pages 32-38

  Gregory Evans, Kevin ^a,b   Po, Kelvin ^a   Chang, Francis ^b   Gregory Evans, Cheryl Y ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Gene therapy; Retinitis pigmentosa; Stem cells

Indexed keywords

GENTAMICIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; EMBRYO; EMBRYONIC STEM CELL; EX VIVO GENE TRANSFER; GENETIC ENGINEERING; HISTOPATHOLOGY; MOUSE; NEUROPROTECTION; NONHUMAN; PHOTORECEPTOR CELL; PRIORITY JOURNAL; RAT; RETINA; RETINA DEGENERATION; RETINITIS PIGMENTOSA; TREATMENT OUTCOME;

ANIMALS; CELL COUNT; CELL SURVIVAL; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; EMBRYONIC STEM CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; GENTAMICINS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INJECTIONS, SUBCUTANEOUS; PROTEIN SYNTHESIS INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RETINITIS PIGMENTOSA; TRANSFECTION;

EID: 79959204373     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000325730     Document Type: Article

References (53)

1. Moosajee M, Gregory-Evans K, Ellis CD, Seabra MC, Gregory-Evans CY: Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease. Hum Mol Genet 2008; 17: 3987-4000. (Pubitemid 352762859)
2. Mendes HF, Cheetham ME: Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa. Hum Mol Genet 2008; 17: 3043-3054.
3. Tan MH, Smith AJ, Pawlyk B, Xu X, Liu X, Bainbridge JB, Basche M, McIntosh J, Tran HV, Nathwani A, Li T, Ali RR: Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors. Hum Mol Genet 2009; 18: 2099-2114.
4. Lu B, Malcuit C, Wang S, Girman S, Francis P, Lemieux L, Lanza R, Lund R: Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells 2009; 27: 2126-2135.
5. Shire DB, Kelly SK, Chen J, Doyle P, Gingerich MD, Cogan SF, Drohan WA, Mendoza O, Theogarajan L, Wyatt JL, Rizzo JF: Development and implantation of a minimally invasive wireless subretinal neurostimulator. IEEE Trans Biomed Eng 2009; 56: 2502-2511.
6. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bennicelli JL, Ying GS, Rossi S, Fulton A, Marshall KA, Banfi S, Chung DC, Morgan JI, Hauck B, Zelenaia O, Zhu X, Raffini L, Coppieters F, de Baere E, Shindler KS, Volpe NJ, Surace EM, Acerra C, Lyubarsky A, Redmond TM, Stone E, Sun J, McDonnell JW, Leroy BP, Simonelli F, Bennett J: Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009; 374: 1597-1605.
7. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR: Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231-2239. (Pubitemid 351724452)
8. Caspi A, Dorn JD, McClure KH, Humayun MS, Greenberg RJ, McMahon MJ: Feasibility study of a retinal prosthesis: spatial vision with a 16-electrode implant. Arch Ophthalmol 2009; 127: 398-401.
9. Cottet S, Schorderet DF: Mechanisms of apoptosis in retinitis pigmentosa. Curr Mol Med 2009; 9: 375-383.
10. Ding X, Patel M, Chan CC: Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 2009; 28: 1-18.
11. Ramaswamy S, Soderstrom KE, Kordower JH: Trophic factors therapy in Parkinson's disease. Prog Brain Res 2009; 175: 201-216.
12. Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, LaVail MM: Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor. Nature 1990; 347: 83-86.
13. Wenzel A, Grimm C, Samardzija M, Remé CE: Molecular mechanisms of light-induced photoreceptor apoptosis and neuroprotection for retinal degeneration. Prog Retin Eye Res 2005; 24: 275-306. (Pubitemid 40021788)
14. MacDonald IM, Sauvé Y, Sieving PA: Preventing blindness in retinal disease: ciliary neurotrophic factor intraocular implants. Can J Ophthalmol 2007; 42: 399-402. (Pubitemid 46932032)
15. Greenfield DS, Girkin C, Kwon YH: Memantine and progressive glaucoma. J Glaucoma 2005; 14: 84-86. (Pubitemid 40165498)
16. Fu QL, Li X, Yip HK, Shao Z, Wu W, Mi S, So KF: Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Neuroscience 2009; 162: 375-382.
17. Osborne NN: Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009; 87: 450-454.
18. Gregory-Evans K, Chang F, Hodges MD, Gregory-Evans CY: Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration. Mol Vis 2009; 15: 962-973.
19. Guerin K, Gregory-Evans CY, Hodges MD, Moosajee M, Mackay DS, Gregory-Evans K, Flannery JG: Systemic aminoglycoside treatment in rodent models of retinitis pigmentosa. Exp Eye Res 2008; 87: 197-207.
20. Glybina IV, Kennedy A, Ashton P, Abrams GW, Iezzi R: Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats. Invest Ophthalmol Vis Sci 2010; 51: 4243-4252.
21. Rowe SM, Clancy JP: Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. BioDrugs 2009; 23: 165-174.
22. Steinberg RH, Flannery JG, Naash M, Oh P, Matthes MT, Yasumura D, Lau-Villacorta C, Chen J, LaVail MM: Transgenic rat models of inherited retinal degeneration caused by mutant opsin genes (ARVO abstract 3190). Invest Ophthalmol Vis Sci 1996; 37:S698. (Pubitemid 126824667)
23. Green ES, Menz MD, LaVail MM, Flannery JG: Characterization of rhodopsin mis-sorting and constitutive activation in a transgenic rat model of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2000; 41: 1546-1553. (Pubitemid 30261882)
24. Chen J, Makino CL, Peachey NS, Baylor DA, Simon MI: Mechanisms of rhodopsin inactivation in vivo as revealed by a COOH-terminal truncation mutant. Science 1995; 267: 374-377.
25. Berson EL, Rosner B, Weigel-DiFranco C, Dryja TP, Sandberg MA: Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations. Invest Ophthalmol Vis Sci 2002; 43: 3027-3036. (Pubitemid 34977056)
26. Duncan TE, O'Steen WK: The diurnal susceptibility of rat retinal photoreceptors to light-induced damage. Exp Eye Res 1985; 41: 497-507. (Pubitemid 16206256)
27. Müller F-J, Snyder EY, Loring JF: Gene therapy: can neural stem cells deliver? Nat Rev Neurosci 2006; 7: 75-84. (Pubitemid 41828933)
28. Meyer JS, Katz ML, Maruniak JA, Kirk MD: Embryonic stem cell-derived neural progenitors incorporate into degenerating retina and enhance the survival of host photoreceptors. Stem Cells 2006; 24: 274-283. (Pubitemid 44464795)
29. Joly S, Pernet V, Chemtob S, di Polo A, Lachapelle P: Neuroprotection in the juvenile rat model of light-induced retinopathy: evidence suggesting a role for FGF-2 and CNTF. Invest Ophthalmol Vis Sci 2007; 48: 2311-2320. (Pubitemid 351261311)
30. McGill TJ, LaVail MM, Douglas RM, Lowe RJ, Yasumura D, Donohue-Rolfe KM, Matthes MT, Duncan JL, Prusky GT: Discrepant anatomical, electrophysiological, and behavioral profiles of retinal degeneration in rat models of retinal degenerative disease (ARVO abstract 3448). Invest Ophthalmol Vis Sci 2007; 48.
31. Du M, Jones JR, Lanier J, Keeling KM, Lindsey JR, Tousson A, Bebök Z, Whitsett JA, Dey CR, Colledge WH, Evans MJ, Sorscher EJ, Bedwell DM: Aminoglycoside suppression of a premature stop mutation in a Cftr-/-mouse carrying a human CFTR-G542X transgene. J Mol Med 2002; 80: 595-604.
32. Welch EM, Barton ER, Zhuo J: PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87-91. (Pubitemid 46685839)
33. Goldmann T, Overlack N, Wolfrum U, Nagel-Wolfrum K: PTC124-mediated readthrough of a nonsense mutation causing Usher type 1C. Hum Gene Ther 2011, E-pub ahead of print.
34. Suzuki M, McHugh J, Tork C, Shelley B, Hayes A, Bellantuono I, Aebischer P, Svendsen CN: GDNF-secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE 2007; 2:e689.
35. Wang S, Girman S, Lu B, Bischoff N, Holmes T, Shearer R, Wright LS, Svendsen CN, Gamm DM, Lund RD: Long-term vision rescue by human neural progenitors in a rat model of photoreceptor degeneration. Invest Ophthalmol Vis Sci 2008; 49: 3201-3206.
36. Pang JJ, Chang B, Hawes NL, Hurd RE, Davisson MT, Li J, Noorwez SM, Malhotra R, McDowell JH, Kaushal S, Hauswirth WW, Nusinowitz S, Thompson DA, Heckenlively JR: Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA). Mol Vis 2005; 11: 152-162. (Pubitemid 41358297)
37. Andrieu-Soler C, Aubert-Pouëssel A, Doat M, Picaud S, Halhal M, Simonutti M, Venier-Julienne MC, Benoit JP, Behar-Cohen F: Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1/rd1 mouse. Mol Vis 2005; 11: 1002-1011. (Pubitemid 41715739)
38. Buch PK, MacLaren RE, Durán Y, Balaggan KS, MacNeil A, Schlichtenbrede FC, Smith AJ, Ali RR: In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration. Mol Ther 2006; 14: 700-709. (Pubitemid 44480755)
39. LaVail MM, Yasumura D, Matthes MT, Lau-Villacorta C, Unoki K, Sung CH, Steinberg RH: Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci 1998; 39: 592-602. (Pubitemid 28110693)
40. Thanos CG, Bell R, O'Rourke P, Kauper K, Sherman S, Stabila P, Tao W: Sustained secretion of ciliary neurotrophic factor to the vitreous using the encapsulated cell therapybased NT-501 intraocular device. Tissue Eng 2004; 10: 1617-1622. (Pubitemid 40054203)
41. Machida S, Chaudhry P, Shinohara T, Singh DP, Reddy VN, Chylack LT Jr, Sieving PA, Bush RA: Lens epithelium-derived growth factor promotes photoreceptor survival in light-damaged and RCS rats. Invest Ophthalmol Vis Sci 2001; 42: 1087-1095. (Pubitemid 32289808)
42. Cayouette M, Smith SB, Becerra SP, Gravel C: Pigment epithelium-derived factor delays the death of photoreceptors in mouse models of inherited retinal degenerations. Neurobiol Dis 1999; 6: 523-532. (Pubitemid 30036622)
43. Léveillard T, Mohand-Saïd S, Lorentz O, Hicks D, Fintz AC, Clérin E, Simonutti M, Forster V, Cavusoglu N, Chalmel F, Dollé P, Poch O, Lambrou G, Sahel JA: Identification and characterization of rod-derived cone viability factor. Nat Genet 2004; 36: 755-759. (Pubitemid 38886639)
44. Bok D, Yasumura D, Matthes M, Ruiz A, Duncan JL, Chappelow AV, Zolutukhin S, Hauswirth W, LaVail MM: Effects of adenoassociated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation. Exp Eye Res 2002; 74: 719-735. (Pubitemid 34948372)
45. Lee SB, Geroski DH, Prausnitz MR, Edelhauser HF: Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems. Exp Eye Res 2004; 78: 599-607. (Pubitemid 38183339)
46. Ogilvie JM, Speck JD, Lett JM: Growth factors in combination, but not individually, rescue rd mouse photoreceptors in organ culture. Exp Neurol 2000; 161: 676-685. (Pubitemid 30137024)
47. Sharma HS: Selected combination of neurotrophins potentiate neuroprotection and functional recovery following spinal cord injury in the rat. Acta Neurochir Suppl 2010; 106: 295-300.
48. Yan Q, Wang J, Matheson CR, Urich JL: Glial cell line-derived neurotrophic factor (GDNF) promotes the survival of axotomized retinal ganglion cells in adult rats: comparison to and combination with brainderived neurotrophic factor (BDNF). J Neurobiol 1999; 38: 382-390. (Pubitemid 29061915)
49. Campbell M, Nguyen AT, Kiang AS, Tam LC, Gobbo OL, Kerskens C, Ni Dhubhghaill S, Humphries MM, Farrar GJ, Kenna PF, Humphries P: An experimental platform for systemic drug delivery to the retina. Proc Natl Acad Sci USA 2009; 106: 17817-17822.
50. Dalkara D, Kolstad KD, Caporale N, Visel M, Klimczak RR, Schaffer DV, Flannery JG: Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 2009; 17: 2096-2102.
51. Cheng JW, Li Y, Wei RL: Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost. Ophthalmic Res 2009; 42: 99-105.
52. Agarwal M, Ganesh SK, Biswas J: Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm 2006; 14: 333-339. (Pubitemid 44949891)
53. Paskowitz DM, Donohue-Rolfe KM, Yang H, Yasumura D, Matthes MT, Hosseini K, Graybeal CM, Nune G, Zarbin MA, Lavail MM, Duncan JL: Neurotrophic factors minimize the retinal toxicity of verteporfin photodynamic therapy. Invest Ophthalmol Vis Sci 2007; 48: 430-437. (Pubitemid 47251434)